A detailed history of Price T Rowe Associates Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 130,761 shares of IBRX stock, worth $708,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130,761
Previous 123,879 5.56%
Holding current value
$708,724
Previous $667,000 24.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.82 - $9.15 $33,171 - $62,970
6,882 Added 5.56%
130,761 $828,000
Q1 2024

May 15, 2024

BUY
$3.23 - $6.17 $14,641 - $27,968
4,533 Added 3.8%
123,879 $667,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $5.21 $11,042 - $46,025
8,834 Added 7.99%
119,346 $601,000
Q3 2023

Nov 14, 2023

SELL
$1.29 - $3.1 $41,316 - $99,286
-32,028 Reduced 22.47%
110,512 $187,000
Q2 2023

Aug 14, 2023

SELL
$1.53 - $6.41 $37,053 - $155,237
-24,218 Reduced 14.52%
142,540 $398,000
Q1 2023

May 15, 2023

BUY
$1.35 - $4.78 $22,680 - $80,304
16,800 Added 11.2%
166,758 $304,000
Q4 2022

Feb 14, 2023

SELL
$4.35 - $6.77 $34,399 - $53,537
-7,908 Reduced 5.01%
149,958 $760,000
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $40,693 - $71,688
11,149 Added 7.6%
157,866 $785,000
Q2 2022

Aug 15, 2022

SELL
$2.68 - $6.14 $49,322 - $113,000
-18,404 Reduced 11.15%
146,717 $546,000
Q1 2022

May 16, 2022

SELL
$5.05 - $7.53 $132,719 - $197,895
-26,281 Reduced 13.73%
165,121 $926,000
Q4 2021

Feb 14, 2022

BUY
$5.67 - $10.18 $52,731 - $94,674
9,300 Added 5.11%
191,402 $1.16 Million
Q3 2021

Nov 15, 2021

SELL
$9.17 - $14.24 $301,748 - $468,581
-32,906 Reduced 15.3%
182,102 $1.77 Million
Q2 2021

Aug 16, 2021

BUY
$13.41 - $22.4 $161,858 - $270,368
12,070 Added 5.95%
215,008 $3.07 Million
Q1 2021

May 17, 2021

BUY
$12.83 - $42.25 $2.6 Million - $8.57 Million
202,938 New
202,938 $4.82 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $2.17B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.